Which mechanism terminates the neuromuscular effects of an intubating dose of vecuronium?

Which mechanism terminates the neuromuscular effects of an intubating dose of vecuronium?

• A. Pseudocholinesterase
• B. Nonspecific plasma cholinesterases
• C. The liver
• D. Diffusion from the neuromuscular junction back into the plasma

Answer: (D)

The main idea is that the offset of a nondepolarizing neuromuscular blocker like vecuronium happens primarily through diffusion away from the neuromuscular junction back into the plasma, which reduces receptor occupancy and allows acetylcholine to regain control of the receptor. This rapid redistribution from the end plate is the key early mechanism that terminates the blocking effect, occurring faster than enzymatic breakdown in the blood or liver metabolism. Pseudocholinesterase enzymes in plasma do not metabolize vecuronium, so they don’t terminate its effect. The liver does metabolize vecuronium, but that process is slower and contributes to recovery after the initial diffusion-driven unoccupying of receptors rather than causing the immediate cessation of blockade.

The main idea is that the offset of a nondepolarizing neuromuscular blocker like vecuronium happens primarily through diffusion away from the neuromuscular junction back into the plasma, which reduces receptor occupancy and allows acetylcholine to regain control of the receptor. This rapid redistribution from the end plate is the key early mechanism that terminates the blocking effect, occurring faster than enzymatic breakdown in the blood or liver metabolism.

Pseudocholinesterase enzymes in plasma do not metabolize vecuronium, so they don’t terminate its effect. The liver does metabolize vecuronium, but that process is slower and contributes to recovery after the initial diffusion-driven unoccupying of receptors rather than causing the immediate cessation of blockade.